Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Prediction of mutational tolerance in HIV-1 protease and reverse transcriptase using flexible backbone protein design.PLoS computational biology · 2012
   Article
2. Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.Antimicrobial agents and chemotherapy · 2011
   Article
3. The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.Retrovirology · 2011
   Article
4. Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase.Journal of acquired immune deficiency syndromes (1999) · 2011
   Article
5. Retroviral reverse transcriptases.Cellular and molecular life sciences : CMLS · 2010
   Review
6. HIV-1 Ribonuclease H: Structure, Catalytic Mechanism and Inhibitors.Viruses · 2010
   Article
7. The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.Viruses · 2010
   Article
8. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms.The Journal of biological chemistry · 2008
   Article
9. HIV treatment proceeds as prevention research confounds.PLoS medicine · 2007
   Article

Corrections and comments

• Comment on
  N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.2007

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as